Salarius Pharmaceuticals, Inc. and VolitionRx Limited announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q(R) technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q(R) has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.954 USD | -1.16% |
|
-19.65% | -43.20% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.20% | 1.78M | |
+34.40% | 51.07B | |
-8.06% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+12.10% | 26.35B | |
-18.91% | 19.46B | |
+41.28% | 13.58B | |
+29.49% | 12.46B | |
-4.06% | 11.75B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement